This post was originally published on this site
The CDC’s immunization panel is scheduled to vote on the vaccines at a Sept. 12 meeting, a notice posted on the federal register website showed.
Vaccine makers such as Pfizer (NYSE:PFE) and its German partner BioNTech SE (NASDAQ:BNTX), Moderna (NASDAQ:MRNA) and Novavax (NASDAQ:NVAX) have created versions of their shots aimed at the XBB.1.5 subvariant of the virus.
CDC Director Mandy Cohen said earlier this month the vaccines were anticipated to be available by the third or fourth week of September, after being recommended by the CDC and authorized by the U.S. Food and Drug Administration.
